Our biomarkers can be used individually or in combination to indicate abnormal lung tissue remodeling, wound healing, and inflammation. Biomarkers have been shown to be elevated in patients with progressive IPF and to function as pharmacodynamic biomarkers.
Our tissue-derived Protein Fingerprint biomarkers can quantify structural tissue changes in the lungs of patients with asthma. Our biomarkers are elevated in asthma patients and are associated with different subtypes.
Our tissue-derived protein fingerprint biomarkers can quantify structural tissue changes in the lungs of patients with COPD. Our biomarkers are related to disease activity in COPD patients and are successful in predicting mortality.
Please don't hesitate to contact us if you have any questions or other inquiries.